Recombinant Human MRC1(Leu19-Lys1383 (Thr399Ala) & (Leu407Phe)) fused with His tag at C-terminal was expressed in NS0.
Predicted N Terminal:
Lyophilized from a 0.2 μm filtered solution in PBS with BSA as a carrier protein.
Measured by its binding ability in a functional ELISA. When Mannan is coated at 0.2 μg/mL (100 μL/well), the concentration of Recombinant Human MMR/CD206 that produces 50% of the optimal binding response is approximately 0.2-1.2 μg/mL.
Predicted Molecular Mass: 157 kDa;SDS-PAGE: 180 kDa, reducing conditions.
Leu19-Lys1383 (Thr399Ala) & (Leu407Phe)
<0.01 EU per 1 μg of the protein by the LAL method.
>90%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Avoid repeated freeze-thaw cycles.12 months from date of receipt, -20 to -70 centigrade as supplied.1 month, 2 to 8 centigrade under sterile conditions after reconstitution.3 months, -20 to -70 centigrade under sterile conditions after reconstitution.
Reconstitute at 100 μg/mL in sterile PBS containing at least 0.1% human or bovine serum albumin.